常规多参数MRI时代下的局限性前列腺癌局灶治疗
本文综述了原发性前列腺局灶治疗(冷冻治疗、HIFU等)的肿瘤学和功能结局,并探讨常规多参数MRI(mpMRI)对患者选择和病灶定位的影响。中危患者的中期前瞻性数据显示可接受的肿瘤控制及低副作用风险,但长期数据仍缺乏。广泛采用mpMRI改善了病灶定位,使局灶治疗成为低体积中危前列腺癌患者的可行策略。
要点
- mpMRI改善病灶定位,助力局灶治疗患者选择与精准实施
- 中危患者中期数据显示HIFU和冷冻治疗肿瘤控制可接受且副作用低
- 尚需明确随访方案及野内/野外复发管理,多项随机对照试验正在进行
核心结论
- 广泛采用前列腺mpMRI改善了疾病定位,使局灶治疗成为低体积中危前列腺癌患者的可行治疗策略。
研究设计与样本
- 本文为文献综述,总结接受原发性前列腺局灶治疗男性的肿瘤学和功能结局,并讨论常规mpMRI对患者选择和治疗实施的影响。
主要发现
- 原发性局灶治疗涉及冷冻治疗和高强度聚焦超声(HIFU)等多种消融能量,成功主要取决于高度准确的患者选择和疾病定位。
- 针对中危疾病男性的原发性HIFU和冷冻治疗前瞻性中期随访数据显示可接受的肿瘤控制及低副作用和并发症风险。
临床怎么用
- 常规整合活检前mpMRI以改善疾病定位,从而支持局灶治疗的患者选择和精准实施。
- 对低体积中危前列腺癌患者,可考虑将局灶治疗作为可行策略,但需注意随访和复发管理尚待明确。
局限性
- 前列腺癌的多灶性特征及局灶治疗长期肿瘤学数据缺乏仍是关注点。
- 适当的随访方法及野内和野外复发的管理仍需进一步研究明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer focal therapy aims to minimize the side-effects of whole gland treatments, such as radical prostatectomy and radiotherapy without compromising oncological efficacy. However, concerns exist regarding the multifocal nature of prostate cancer and the lack of long-term oncological data for this form of treatment. In recent years, the routine adoption of multi-parametric magnetic resonance imaging (mpMRI) of the prostate has improved our ability to select candidates for focal therapy and to accurately deliver this form of prostate cancer treatment. METHODS: We performed a review of the literature to provide a summary of the oncological and functional outcomes of men receiving primary prostate focal therapy. Furthermore, we discuss the impact of the routine implementation of mpMRI as part of the initial prostate cancer diagnostic pathway on the selection of candidates and delivery of focal therapy. Finally, we summarize knowledge gaps in the field and highlight active clinical trials in this arena. RESULTS: Primary focal therapy involves the application of one of a number of energies that ablate tissue, such as cryotherapy and high intensity focused ultrasound (HIFU). Success is principally dependent on highly accurate patient selection and disease localization underpinned in large part by the routine integration of pre-biopsy mpMRI. Prospective medium-term follow-up data for primary HIFU and cryotherapy for men with intermediate-risk disease have shown acceptable cancer control with low risk of side effects and complications. Additional research is needed to clearly define an appropriate follow-up approach and to guide the management of in- and out-of-field recurrences. Multiple comparative trials with randomization against standard care are currently underway in men with intermediate- and high-risk prostate cancer. CONCLUSION: The widespread adoption of prostate mpMRI has led to improved disease localization, enabling the performance of focal therapy as a viable treatment strategy for men with low volume intermediate-risk prostate cancer.
引用
- Connor MJ, Gorin MA, Ahmed HU, et al. Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. Prostate Cancer Prostatic Dis. 2020. PMID: 32051551. doi:10.1038/s41391-020-0206-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。